Recent Updates
Recently added Catalysts
IKT Positive Sentiment Score: 80/100

By electronic delivery to: mhwerner@inhibikase.com; jfrattaroli@inhibikase.com

Monday, July 17, 2023 1 min read
Key Takeaway: Inhibikase Therapeutics has successfully regained compliance with Nasdaq Listing Rule 5550(a)(2) after its common stock fell below the required minimum bid price of $1.00. The company met the necessary conditions by maintaining a closing bid price of $1.00 per share or greater for the past 10 consecutive business days. This development signals a positive turnaround for the company in terms of stock market compliance.

Market Sentiment Analysis

POSITIVE FACTORS

  • Inhibikase Therapeutics has regained compliance with Nasdaq Listing Rule 5550(a)(2).
  • The company's stock price has been at or above $1.00 for the last 10 consecutive business days.
  • Success in maintaining the required minimum bid price enhances investor confidence.

Full Press Release Details

By electronic delivery to: mhwerner@inhibikase.com; jfrattaroli@inhibikase.com
Dr. Milton H. Werner
Chief Executive Officer
Inhibikase Therapeutics, Inc.
3350 Riverwood Parkway SE, Suite 1900
Atlanta, Georgia 30339
July 25, 2022, Staff notified the Company that its common stock failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days as required by the Listing Rules of The Nasdaq Stock Market. Since then, Staff has
determined that for the last 10 consecutive business days, from June 30, 2023, through July 14, 2023, the closing bid price of the Company s common stock has been at $1.00 per share or greater. Accordingly, the Company has regained
compliance with Listing Rule 5550(a)(2) and this matter is now closed.
If you have any questions, please contact Ms. Brie Charles at +1 301 978
Nasdaq Listing Qualifications

Frequently Asked Questions

What is the main issue addressed in the letter?

The letter addresses a compliance issue regarding Inhibikase's stock price.

What was the minimum bid price required by Nasdaq?

The minimum bid price required by Nasdaq was $1.00.

When did the compliance issue occur?

The compliance issue occurred before June 30, 2023.

How did Inhibikase regain compliance?

Inhibikase regained compliance by maintaining a closing bid price above $1.00.

Who should be contacted for questions?

Questions should be directed to Ms. Brie Charles at +1 301 978.

Tags: IKT Viatris Investor Conferences Healthcare Inhibikase Nasdaq Listing Rules stock price
Last updated: Jul 17, 2023